Therachon, a clinical-stage biotechnology company, has appointed Aled Williams to the position of chief commercial officer and head of patient access.
Williams has more than 25 years’ experience in healthcare and pharmaceuticals and most recently he served as vice president and global strategy head for rare gastrointestinal diseases at Shire.
There he was responsible for the commercialisation and development of Gattex/Revestive (teduglutide) for short bowel syndrome.
Williams said: “I am excited to be joining the talented leadership team at Therachon and I look forward to working with the Therachon team and the whole medical and patient community in developing TA-46, and advancing Therachon’s pipeline of drug candidates that aim to bring a transformational new therapy to those in the achondroplasia community.”
Prior to his time at Shire, Williams held leadership positions at Bristol-Myers Squibb, Novartis and Roche.
Commenting on the recent appointment, Luca Santarelli, chief executive officer of Therachon, said: “Aled has spent many years leading companies through the development of successful rare disease programmes, including the expansion of patient outreach and commercial capabilities.
“We believe his considerable leadership experience in rare diseases will contribute to Therachon’s continued growth as we move into the clinic, establish our network of key partners among clinicians and patient organisations.”